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Due to its non-pathogenic lifecycle, little is known about the cellular determinants of infection by
adeno-associated virus (AAV). To identify these critical cellular factors, we took advantage of the gene
transfer abilities of AAV in combination with a forward genetic selection to identify proteins critical for
transduction by this virus. AAV serotype 5 (AAV5) vectors encoding the furin gene were used to
transduce furin-deﬁcient cells followed by selection with furin-dependent toxins. A population of cells
speciﬁcally resistant to AAV5 transduction was identiﬁed and sequence analysis suggested all had a
single amino acid mutation in the leader sequence of the platelet-derived growth factor receptor alpha
(PDGFRa) gene. Characterization of this mutation suggested it inhibited PDGFRa trafﬁcking resulting in
limited expression on the plasma membrane. Mutagenesis and transfection experiments conﬁrmed the
effect of this mutation on PDGFRa trafﬁcking, and the AAV5 resistant phenotype could be rescued by
transfection with wild type PDGFRa.
Published by Elsevier Inc.Introduction
The entry process of a virus into a cell is not strictly determined
by the virus but is very much dependent upon the proteins that are
expressed by the cell and the interactions that occur between the
virus and these proteins. Identiﬁcation of these proteins has not
only resulted in development of antiviral therapies but has also
advanced our understanding of cell biology. Identiﬁcation of the
receptor(s) or intracellular proteins associated with viral infection
can be a formidable task. In addition to the use of engineered cell
lines and biochemical assays, several powerful genomic techniques
have been used to accomplish this task. These include a radiation
hybrid approach that identiﬁed the receptor for jaagsiekte virus
entry (Rai et al., 2001) and a bioinformatics-based approach termed
comparative genome analysis (CGA) developed in our laboratory
which identiﬁed a receptor for adeno-associated virus type 5Inc.
th, 16 National Institute of
, 10 Center Dr., 17 MSC1190,
urg.de (I.H. Pilz),
zinska),
.gov (J.A. Chiorini).
nternal Medicine II, Freiburg,(AAV5) and AAV6 and several genes important to the infection of
Ebola virus (Brindley et al., 2011; Di Pasquale et al., 2003;
Kondratowicz et al., 2011; Quinn et al., 2009; Weller et al., 2010).
While these approaches have been successful, each has limitations.
Genetic selection is a powerful approach for understanding com-
plex biological processes. While reverse genetics is a common
approach for understanding the function of a known gene by
deleting it, forward genetics uses selective pressure on hemizygous
cells to identify genes conferring a speciﬁc phenotype. Genetic
screens using gene knockout techniques or complementation with
cDNA libraries followed by selection have been used to identify
genes involved in apoptosis or cytokine response pathways (Kumar
et al., 1997; Velazquez et al., 1992).
In this study we investigated whether forward genetic selec-
tion could help to understand critical steps in virus infection
processes. As a model virus, we chose AAV5. While AAV5 is not
associated with any disease, vectors based on this virus have
utility for gene transfer to the eye and lung as well as for
delivering a genetic vaccination against viral agents (Alexander
et al., 2007; Kuck et al., 2006; Zabner et al., 2000). Efﬁcient
transduction with AAV5 is known to require both N-linked a2–3
sialic acid as an attachment receptor as well as expression of the
platelet-derived growth factor receptors (PDGFRa) for internali-
zation (Di Pasquale et al., 2003; Kaludov et al., 2001). However,
other proteins are likely to be important in this process. Following
selection of a spontaneously mutated cell population for variants
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PDGFRa in AAV5 transduction and identiﬁed a region in the
leader sequence of PDGFRa which is responsible for the proper
trafﬁcking of this protein. Transfection experiments demon-
strated that the AAV5-resistant phenotype could be rescued by
wild type PDGFRa.Experimental procedures
Construction of AAV2F, AAV5F, AAV2B and AAV5B and vector
production
A HindIII and BlpI fragment containing the furin cDNA was
isolated from the pAGEFur plasmid (Hatsuzawa et al., 1990) and
ligated into HindIII- and BlpI-digested AAV2rnLacZ and AAV5rn-
LacZ plasmids to create AAV2F and AAV5F plasmids, respectively.
AAV2B and AAV5B encoding the beta galactosidase gene were
previously described (Kaludov et al., 2001). Recombinant particles
were produced in 293T cells as previously described (Alisky et al.,
2000).
Cloning of cDNA
RNA was isolated from CHO cells by extraction of the cells with
Triazol (Invitrogen, Carlsbad, CA). DNA was synthesized using the
Smart Race kit (Clontech, Mountain View, CA) and sequenced
using a series of primers based on regions conserved across the
mouse, rat, and human cDNAs of PDGFRa. Plasmids expressing
either human or CHO PDGFRa were assembled and expressed
in the DualGC vector (Stratagene) using the CMV promoter
(phPDGFRa or pcPDGFRa respectively).
Cell culture
CHO-K1 (ATCC CCL-61) and CHO FD11 cells (Gordon et al.,
1995), were cultured at 37 1C, 5% CO2 in alpha minimal essential
medium (AMEM) (Bioﬂuids) supplemented with 10% fetal bovine
serum, 100 mg/ml penicillin, and 100 mg/ml streptomycin. A549
cells were maintained at 37 1C, 5% CO2 in HAMs F12 and D10
medium (Dulbecco’s modiﬁed Eagle’s medium) containing 10%
fetal bovine serum, 100 mg/ml penicillin, and 100 mg/ml strepto-
mycin. Madin–Darby Canine Kidney (MDCK) cells were a gift from
Bob Weller. Cells were cultured at 37 1C, 5% CO2 in Dulbecco’s
modiﬁed essential medium (DMEM) (Bioﬂuids) supplemented
with 10% fetal bovine serum, 100 mg/ml penicillin, and 100 m/ml
streptomycin.
Toxin screen
Sensitivity to Pseudomonas exotoxin A (PE) toxin was deter-
mined by plating 1104 CHO-K1 and CHO FD11 cells and then
incubating them with increasing amounts of PE (List Biologics) for
48 h. Two days post-selection, surviving cells were counted using
a microscope and a calibrated ocular. Sensitivity to anthrax toxins
was determined using protective antigen (PA, List Biologics) from
Bacillus anthracis in combination with fusion protein FP59 (a
fusion of anthrax lethal factor with the catalytic domain of PE
(Gordon et al., 1995; Klimpel et al., 1992)). A modiﬁed form of PA
(PA-RAAR, having amino acids 164-RKKR-167 changed to RAAR)
was also used in the screen to improve the speciﬁcity for cleavage
by furin. CHO-K1 and CHO FD11 cells were incubated with
increasing amounts of PA for 48 h in concert with 20 ng/ml
FP59. Two days post-selection surviving cells were counted using
a microscope and a calibrated ocular.Confocal immunoﬂuorescence
Parental and mutant CHO cells were ﬁxed with 1% paraformal-
dehyde for 15 min at room temperature prior to permeabilizing
with 0.2% Triton X-100 in PBS and blocking. Cell surface PDGFRa
expression was evaluated by incubating non-permeablized cells
with primary mouse monoclonal anti-PDGFRa antibody (1:500)
(Santa Cruz Biotechnology, CA) and secondary antibody (Alexa
Fluor 488 anti-mouse, Molecular Probes) (1:1000).Results
Design of AAV-based genetic selection
A recessive screen involves the identiﬁcation of a change in
phenotype because of the loss of gene expression. An example of
this technique is the use of selection in a polyclonal population in
which mutagenesis or loss of a gene results in a block in gene
expression and alters the cell phenotype. Hemizygotic cells are an
advantage in recessive screens and we chose to use the hemi-
zygous furin-deﬁcient Chinese Hamster Ovary cell mutant CHO
FD11 (Gordon et al., 1995), which has been successfully used in
recessive screens. Although the original FD11 isolate was clonal
following the initial selection, subsequent passages and expan-
sions can result in drift and spontaneous mutations to accumulate
at other hemizygous loci, so that the resulting population of cells
can be useful in subsequent screenings. Thus, the strategy to
identify genes associated with AAV transduction involved trans-
ducing this population of CHO FD11 cells with AAV vectors
encoding furin (AAVF) and then selecting resistant cells with
either PE or PA toxin. To determine which serotypes could be
screened using this strategy, CHO FD11 cells were transduced
with three different serotypes (AAV2, AAV4, AAV5) of AAV
encoding the b-gal gene and their transduction efﬁciencies
compared (Fig. 1a). CHO FD11 cells were permissive for both
AAV2 and AAV5 but resistant to AAV4 transduction. Because
AAV5 exhibited a higher transduction efﬁciency, it was chosen for
the recessive screen.
CHO FD11 transduction and PE selection
To determine the optimal toxin concentration, cell killing
experiments were ﬁrst done using the furin expressing cells
(CHO-K1) and the furin deﬁcient and toxin-resistant CHO FD11
cell line. Concentrations of 0.3 mg/ml PE and 0.03 mg/ml PA were
chosen for use in the screening. All PA selections were carried out
in concert with addition of 20 ng/ml FP59 (Gordon et al., 1995).
An MOI of 500 AAV5F virions/cell led to a 99% kill of the cells
subsequently treated with PE (Fig. 1b), while at an MOI of 1000 no
cells survived. However, even at an MOI of 1000, transduction with
AAV4F did not affect cell viability, conﬁrming the previous data in
Fig. 1a regarding the different cell tropisms of AAV serotypes. From
this data, we concluded that AAV5 transduction (i.e., rAAV5F) could
complement furin deﬁciency in CHO FD11 cells.
Selection of CHO FD11 cells resistant to AAV5 transduction
To conduct the selection, four rounds of transduction were
carried out with increasing amounts of vector on pooled cells. As
AAV vectors tend to remain episomal, they will eventually be lost
in a dividing tissue culture cell population allowing for subse-
quent rounds of selection. To minimize the potential of false
positives that might occur due to resistance to PE selection, the
cells were challenged with PA in the second round of selection
instead of PE and then challenged with PE in subsequent rounds.
Fig. 1. AAV transduction and sensitivity to PE of CHO FD11 cells. (A) Cells were
transduced with AAV2B, AAV4B, or AAV5B and the transduction activity deter-
mined by end point dilution. N¼3. No transduction was observed with AAV4
compared with AAV2 or AAV5. (B) CHO FD11 cells transduced with AAV5F or
AAV4F at increasing MOIs were challenged with PE for 48 h and the number of
surviving cells was counted. Cells treated with PBS were included as a control.
CHO FD11 cells transduced with AAV5 were very sensitive to toxin compared with
AAV4-treated cells.
Table 1
Selection of CHO FD11 cells resistant to AAV5 transduction. The data summarize the
number of colonies obtained after each round of selection. The colony number was
calculated for MOI¼700 transductions by measuring the average number of
colonies per cm2. For MOIs of 3500 and 7000, colonies were counted directly.
Resistance phenotypes of isolated colonies to AAV5 transduction (two columns at
right) were determined by transduction with AAV encoding b-galactosidase and
the titer compared to that of the parent cells. Resistance to AAV5 is deﬁned as a
410-fold decrease in transduction with AAV5b-gal. Two parallel selections were
performed at round 4.
Selection
round
Selection
conditions
Surviving colonies Phenotype of
surviving colonies
Cells
transduced
MOI Number Percent of
cells
plated
Colonies
tested
Colonies
resistant to
AAV5
1 2106 700 39800 2 159 1
2 1105 700 23000 23 – –
3 1105 700 44250 44 30 1
4a 1104 3500 20 0.2 20 11
4b 1104 7000 13 0.13 13 7
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observed to increase suggesting a selection of resistant cells. In
the ﬁnal round at an MOI of 3500, 11 of the 20 colonies tested had
a decrease in transduction with AAV5 of at least 10-fold. At an
MOI of 7000, seven clones out of 13 exhibited a decrease in
transduction with AAV5 vectors compared to CHO FD11 (Table 1).
Overall the transduction activity of AAV5 decreased 10–1000 fold
while the activity of AAV2 (another AAV serotype with distinct
cell tropism and cell binding activities) was not affected. This
ﬁnding suggests the mutation(s) in the selected clones are speciﬁc
to AAV5 transduction.
Characterization of CHO FD11 cells resistant to AAV5 transduction
Previous data from our group demonstrated that the PDGFRa
plays a key role in AAV5 transduction by serving as an inter-
nalization receptor for virus entry (Di Pasquale et al., 2003). To
test if PDGFRa expression had changed in the transduction-
resistant clones, cell lysates were prepared from two clones
(clones 1 and 11) and a western blot was probed with anti-
PDGFRa antibody (Fig. 2a). This blot suggested a similar level of
expression for the two clones compared with the WT parent, but a
higher mobility for the major band, which migrated at a position
similar to that of a minor band in the WT PDGFRa. Five other
randomly selected clones with resistance to AAV5 transductionfrom the MOI 3500 and 7000 selections were also tested and
yielded the same banding patterns (data not shown). This
suggests that these clones may be siblings and that this mutation
was present early in the selection process and was expanded
during subsequent selections. Human PDGFRa is glycosylated at
as many as nine sites, with the added glycans accounting for up to
20% of the apparent molecular weight (Daniel et al., 1987). To
distinguish whether the difference in mobility was the result of
a change in glycosylation or in the protein sequence, cells were
treated with tunicamycin to block the addition of N-linked
carbohydrates to the protein. Tunicamycin treatment resulted in
a similar mobility for the PDGFRa in the parental cells and clones
1 (MOI 3500 selection) and 11 (MOI 7000 selection), suggesting
that the original difference in mobility was indeed due to
decreased glycosylation of PDGFRa (Fig. 2a).
The change in glycosylation could be the result of alterations to
either the primary sequence of the CHO FD11 PDGFRa, the cellular
enzymes responsible for the addition of carbohydrates, or intra-
cellular trafﬁcking. To clarify the mechanism of this change in
glycosylation, we cloned and sequenced the PDGFRa gene from the
WT parental CHO FD11 cells as well as from clones 1 and 11. The
CHO FD11 PDGFRa gene sequence that we determined (and
deposited as Genbank HQ424162) is approximately 91% identical
to the human sequence (data not shown). Sequence alignment of
PDGFRa isolated from clones 1 and 11 with PDGFRa cloned from
the parental CHO FD11 cells identiﬁed a single amino acid change
in both clones as compared to WT, a leucine to proline substitution
at position 18 (L18P). Domain analysis of the sequence of the WT
CHO FD11 PDGFRa indicated that the ﬁrst 23 amino acids con-
stitute the leader sequence, suggesting this mutation could affect
protein trafﬁcking in the cell. The consensus sequence associated
with a peptide leader region of protein is ill-deﬁned but highly
related to the hydrophobicity and structure of the domain (Ryan
and Edwards, 1995). Thus, a substitution of a proline for leucine,
which would both decrease the overall hydrophobicity as well as
introduce a b-turn, could prevent proper trafﬁcking of PDGFRa,
resulting in both the altered glycosylation and lack of cell surface
expression.
To verify that this mutation was responsible for the change in
mobility and glycosylation observed with the PDGFRa in the
mutant clones, site directed mutagenesis was used to correct the
mutation and the corrected gene was transfected into Madin–
Darby Canine Kidney MDCK cells, which have been extensively
used for studying protein trafﬁcking. Transfection of the L18P
mutant or corrected PDGFRa-encoding plasmids generated distinct
Fig. 2. PDGFRa expression and activity. (a) CHO PDGFRa glycosylation was detected by Western blot of whole cell lysates prepared from either untreated (lanes 1–3) or
tunicamycin treated (lane 4–6) parental (lane 1, 4) or CHO FD11 clones 1 or 11 (lanes 2,5 and 3,6, respectively). Blots were probed for PDGFRa expression and mobility
with an anti-PDGFRa antibody. Mobility of molecular weight markers of 148 and 98 kDa are indicated. (b) Altered mobility of the CHO PDGFRa L18P clone compared with
the CHO PDGFRa WT was determined by western blotting of whole cell lysates from MDCK cells transfected with the respective clones and probing with anti-PDGFRa
antibodies. Arrows indicate the speciﬁc bands. Molecular weight markers at 148 and 98 kDa are indicated. (c) Increased AAV5 transduction was observed upon transient
transfection of CHO FD11 clone 1 cells with WT PDGFRa, compared with transfection of the L18P mutant with AAV5 vector expressing LacZ. N¼3.
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ing this amino acid is responsible for the change in mobility and
glycosylation observed in the mutant CHO clones 1 and 11. This
change in molecular weight is similar to that previously reported
for deglycosylated PDGFRa (Daniel et al., 1987).
It would be expected that transfection of the WT PDGFRa
(pcPDGFRa) gene should rescue the phenotype of the CHO
mutants. CHO clone 1 cells were transiently transfected with
either the pcPDGFRa sequence or the L18P mutation and the
relative transduction activity compared to cells transfected with
an empty vector (Fig. 2c). Although only a fraction of the cells
were transfected, PDGFRa expression in the CHO clone 1 cell
population increased the transduction activity of AAV5 by over
4-fold compared with cells transfected with an empty vector
(Po0.05). In contrast, transfection of the PDGFRa gene containing
the L18P mutation increased AAV5 transduction only slightly,
and the change was not statistically signiﬁcant. Similar results
were seen if the cells were transfected with the human version,
phPDGFRa (data not shown).
Altered glycosylation and intracellular trafﬁcking has been
associated with poor cell surface trafﬁcking of membrane
proteins (Vagin, Kraut, and Sachs, 2009). To determine the cell
surface expression of PDGFRa in WT CHO FD11 and clone 1 or
11 cells, non-permeabilized cells were incubated with anti-
PDGFRa antibody followed by a ﬂuorescently labeled secondary
antibody and then counter stained with rhodamine labeled
phalloidin. Compared with control cells, the WT parental CHO
FD11 cells express abundant levels of PDGFRa on their surface
(Fig. 3). In contrast, very little PDGFRa was detected on the
surface of clone 1 or clone 11. Permeabilization of the cells
showed similar levels of PDGFRa expression in all three cell
lines. This ﬁnding suggests that the L18P mutation affects the
trafﬁcking of the PDGFRa receptor and suggests the loss of
AAV5 transduction is the result of altered trafﬁcking of PDGFRa
and lack of surface availability to function as a receptor
for AAV5.Discussion
Forward genetic screens offer a powerful approach for under-
standing complex phenotypes such as virus entry. However, to be
effective, this approach must be combined with strong selection
techniques. By taking advantage of the gene transfer activities of
virus in combination with our increased understanding of toxin
biology, it is possible to achieve the strong selection necessary for a
successful screen. Although not utilized in this study, the incor-
poration of insertional mutagenesis strategies such as retroviral
insertion and gene trap vectors to disrupt gene expression (Carette
et al., 2009; Liu and Leppla, 2003) or the use of large scale siRNA
libraries would further increase the discovery rate. One limitation
in our study is the relatively low transduction rescue of the CHO
FD11 Clone 1 cells. This is likely due to a combination of factors
including low transfection efﬁciency of this clone (o20% at 48 h,
data not shown), and competition from the endogenous mutant
PDGFRa. Alternatively there could be additional mutations that
affect transduction efﬁciency not related to PDGFRa expression.
In addition to conﬁrming the central and likely rate limiting
role of PDGFRa in the lifecycle of AAV5, the identiﬁcation of an
amino acid in the leader sequence necessary for optimal expres-
sion of PDGFRa may be useful in characterizing the trafﬁcking of
this protein in the cell. Mutations in the leader sequence of
PDGFRa have not been previously reported. However, mutations
in the leader sequences of several other genes are associated with
either disease or increased susceptibility to infection (Jarjanazi
et al., 2008). Just as in our ﬁndings with clones 1 and 11, leucine
to proline substitutions have been found in the calcium-sensing
receptor gene, where an L13P substitution is associated with
Familial hypocalciuric hypercalcemia as well as neonatal hyper-
parathyroidism, and in the sonic hedgehog gene, where an L17P
substitution is associated with holoprosencephaly (Kato et al.,
2000; Pidasheva et al., 2005).
We demonstrated that the PDGFRa L18P mutation results in
very low cell surface expression. Mutations in other regions of
Fig. 3. Immunoﬂuorescent staining for PDGFRa. Parental and CHO FD11 Clones 1 and 11 were stained for PDGFRa expression. (A) Cell surface PDGFRa expression was
detected on unpermeabilized cells by staining with anti-PDGFRa (green) and counter staining with phalloidin (red). (B) Intracellular PDGFRa was detected by
permeabilizing the cells with Triton X-100 and then staining with anti-PDGFRa (green). Anti-PDGFRa was omitted in control samples in top row. Limited cell surface
expression was detected in the CHO FD11 clones 1 and 11 cells compared with parental CHO K1 cells. (For interpretation of the references to colour in this ﬁgure legend,
the reader is referred to the web version of this article.)
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phragmatic hernia (CDH) (Bleyl et al., 2007), a common birth
defect with an estimated prevalence of 1 in 2500 live births, is
attributed to 12 different polymorphisms in exons 3–22. Muta-
tions in the promoter region of PDGFRa are associated with low
PDGFRa expression and disease (Wu et al., 2006). In asthma, the
frequency of the PDGFRa low expression allele H1 in either
homozygous or heterozygous genotypes in nonallergic asthmatics
was signiﬁcantly higher compared with controls. In contrast, the
high expression allele H2 was reduced in this population com-
pared with controls. Single nucleotide polymorphism analysis of
the leader peptide of the PDGFRa gene may identify new alleles
associated with these and other diseases.AcknowledgmentsThe authors acknowledge the assistance of Medha Bhagwat
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